Pharmacological inhibition of TKs, such as Abelson (Abl), Discoidin Domain Receptor-1 (DDR1), Platelet Derived Growth Factors (PDGFRα/β) and fused in sarcoma (Src), diminishes AD pathology in APP transgenic mice, suggesting this as a potential therapeutic strategy (Hebron et al, 2017; Fowler et al, 2019). The gene discussed is DDR1; the disease is Alzheimer disease.